1h Free Analyst Time
The publisher has been monitoring the insulin pens market and it is poised to grow by $3.43 billion during 2021-2025, progressing at a CAGR of about 8% during the forecast period. The report on the insulin pens market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of diabetes cases and rising government initiatives to prevent diabetes in developed countries. In addition, the growing prevalence of diabetes cases is anticipated to boost the growth of the market as well.
The insulin pens market analysis includes the product segment and geographic landscape.
The insulin pens market is segmented as below:
By Product
- Reusable insulin pens
- Disposable insulin pens
By Geography
- North America
- Europe
- Asia
- ROW
This study identifies the increasing product launches as one of the prime reasons driving the insulin pens market growth during the next few years.
The report on insulin pens market covers the following areas:
- Insulin pens market sizing
- Insulin pens market forecast
- Insulin pens market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading insulin pens market vendors that include Becton, Dickinson and Co., Biocon Ltd., Eli Lilly and Co., Emperra GmbH E-Health Technologies, Innovation Zed Ltd., Medtronic Plc, Nemera, Novo Nordisk AS, Owen Mumford Ltd., and Sanofi SA. Also, the insulin pens market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Product
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global insulin pens market: Becton, Dickinson and Co., Biocon Ltd., Eli Lilly and Co., Emperra GmbH E-Health Technologies, Innovation Zed Ltd., Medtronic Plc, Nemera, Novo Nordisk AS, Owen Mumford Ltd., and Sanofi SA.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing product launches.'
According to the report, one of the major drivers for this market is the growing prevalence of diabetes cases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Becton Dickinson and Co.
- Biocon Ltd.
- Eli Lilly and Co.
- Emperra GmbH E-Health Technologies
- Innovation Zed Ltd.
- Medtronic Plc
- Nemera
- Novo Nordisk AS
- Owen Mumford Ltd.
- Sanofi SA